Evidence map›Paper›PMID 39585787›Full record

ArticleThe Journal of clinical investigation2024

Elevated microRNA-187 causes cardiac endothelial dysplasia to promote congenital heart disease through inhibition of NIPBL.

Chao Li, Zizheng Tan, Hongdou Li, Xiaoying Yao, Chuyue Peng, Yue Qi, Bo Wu, Tongjin Zhao, Chentao Li, Jianfeng Shen and 1 more

Erratum issuedAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Protocol for Cryopreservation of Endothelial Monolayers: An Update.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  8. Review
  9. Epigenetic Mechanisms in Heart Diseases.Reviews in cardiovascular medicine · 2025
    Review
  10. Article
  11. Genetic and Environmental Contributors To Congenital Heart Disease.Current treatment options in cardiovascular medicine · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Chao LiObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.
Zizheng TanShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, China.
Hongdou LiObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.
Xiaoying YaoObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.
Chuyue PengObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.
Yue QiObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.
Bo WuPrenatal Diagnosis Center of Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, China.
Tongjin ZhaoShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, China.
Chentao LiShanghai Medical College, Fudan University, Shanghai, China.
Jianfeng ShenDepartment of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Hongyan WangObstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Children's Hospital, and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac endothelial cells are essential for heart development, and disruption of this process can lead to congenital heart disease (CHD). However, how microRNAs influence cardiac endothelial cells in CHD remains unclear. This study identified elevated microRNA-187 (miR-187) expression in embryonic heart endothelial cells from CHD fetuses. Using a conditional knockin model, we showed that increased miR-187 levels in embryonic endothelial cells induce CHD in homozygous fetal mice, closely mirroring human CHD. Mechanistically, miR-187 targets NIPBL, which is responsible for recruiting the cohesin complex and facilitating chromatin accessibility. Consequently, the endothelial cell-specific upregulation of miR-187 inhibited NIPBL, leading to reduced chromatin accessibility and impaired gene expression, which hindered endothelial cell development and ultimately caused heart septal defects and reduced heart size both in vitro and in vivo. Importantly, exogenous miR-187 expression in human cardiac organoids mimicked developmental defects in the cardiac endothelial cells, and this was reversible by NIPBL replenishment. Our findings establish the miR-187/NIPBL axis as a potent regulator that inhibits cardiac endothelial cell development by attenuating the transcription of numerous endothelial genes, with our mouse and human cardiac organoid models effectively replicating severe defects from minor perturbations. This discovery suggests that targeting the miR-187/NIPBL pathway could offer a promising therapeutic approach for CHD.

Indexed as

Cell Cycle ProteinsEndothelial CellsHeart Defects, CongenitalMicroRNAsAnimalsHumansMiceCell Cycle ProteinsMicroRNAsCardiologyCardiovascular diseaseDevelopmentNoncoding RNAs

Identifiers

PMID39585787
PMCPMC11684815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.